ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Advisors approve NCI’s revised plan for $104-million proteomics research program.

July 8, 2005

ACCC Seeks Greater Role In Clinical Research Priorities; Suggests Up To 400 Cancer Program

April 13, 1979

FDA Advisors Oppose Group’s Tamoxifen Trial, But Okay The Idea

July 6, 1990

International Group Plans Survey On Thrombosis Risk

July 27, 2001

NCI To End CIS Partnership Program In 2010.

December 5, 2008

Tom Curran Becomes AACR President, Hong Is President-Elect; Attendance 13,000.

April 14, 2000